Agenus Inc.

AGEN

US00847G8042

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2024 BST			5-day change	1st Jan Change
17.73 ^USD	+0.17%		+15.88%	+7.08%

06-28	Sector Update: Health Care Stocks Edge Higher in Afternoon Trading	MT
06-28	Agenus Shares Rise After Trial Shows Tumor Reductions in Colon Cancer Patients	MT

Agenus Inc. announced that it has received $30 million in funding from Gilead Sciences, Inc.

January 22, 2019

On January 23, 2019, Agenus Inc. (NasdaqCM:AGEN) closed the transaction.

Latest news about Agenus Inc.

Sector Update: Health Care Stocks Edge Higher in Afternoon Trading	06-28	MT
Agenus Shares Rise After Trial Shows Tumor Reductions in Colon Cancer Patients	06-28	MT
Agenus Inc Announces Results from an Investigator-Sponsored Trial of Botensilimab and Balstilimab (BOT/BALl) in the Neoadjuvant Setting for Colon Cancer	06-28	CI
Agenus Inc. Announces Availability of Botensilimab for Clinical Studies	06-27	CI
Agenus Appoints Jennifer Buell to Its Board of Directors	06-17	CI
Transcript : Agenus Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM	06-12
Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	05-16	CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	05-07	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	05-07	MT
Transcript : Agenus Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M	05-07	MT
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus? Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program	05-07	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	04-12	MT
Sector Update: Health Care	04-12	MT
Agenus Shares Decline After Update on Early Stage Colorectal Cancer Drug Trial	04-12	MT
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	04-12	CI
Agenus Stockholders Approve 1-for-20 Reverse Stock Split	04-05	MT
B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating	03-18	MT
Transcript : Agenus Inc., Q4 2023 Earnings Call, Mar 14, 2024	03-14
Earnings Flash (AGEN) AGENUS Posts Q4 Revenue $83.8M	03-14	MT
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Agenus Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
Agenus Inc. Announces Preclinical Data on BMS-986442 at AACR 2024	03-06	CI
Ginkgo Bioworks, Agenus Unit Win Contract to Discover, Develop Vaccine Adjuvants	02-15	MT

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Agenus Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.73 USD

Average target price

44.25 USD

Spread / Average Target

+149.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AGENUS INC.	+7.08%	372M
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+49.28%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
CELLTRION, INC.	-4.47%	28.7B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research

Agenus Inc.

Equities

AGEN

US00847G8042

Biotechnology & Medical Research

Agenus Inc. announced that it has received $30 million in funding from Gilead Sciences, Inc.

Latest news about Agenus Inc.

Chart Agenus Inc.

Company Profile

Income Statement Evolution

Ratings for Agenus Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research